Hepatitis-Free Interval After Clotting Factor Therapy in First Infused Haemophiliacs

Summary

Post-infusion hepatitis is known to occur very frequently in haemophiliacs after treatment with unheated commercial clotting factor concentrates, obtained from large plasma donation pool. On the contrary, single-donor cryoprecipitate is likely to carry a lower risk of transmitting hepatitis.

To evaluate this hypothesis, we retrospectively reviewed the medical records of 25 first infused haemophiliacs (from 1981 to 1984) treated with unheated commercial clotting factor concentrates (n = 19) or cryoprecipitate (n = 6).

The hepatitis-free interval after the beginning of therapy was expressed as exposure days. The end point of each patient, i.e. the hepatitis occurrence, was defined as an increase of aminotransferases (ALT and AST) and/or the seroconversion of HBV-markers, which were checked every three months.

The life-table method and log-rank test showed that cryo-precipitates had a significantly longer hepatitis-free interval (p = 0.0131, log-rank test) and a lower risk of transmitting hepatitis (p = 0.01-0.05, life-table method) than the commercial concentrates. However, the safety of cryoprecipitate therapy was shown to cover only a few exposure days, and so the real advantage of this product depends on the bleeding frequency of the patient concerned.

We believe that these methods and our findings may be useful to assess and compare the safety of the new “heat-treated” clotting factor concentrates.

Key words

Post-infusion hepatitis - Clotting factor concentrates - Logrank test

• References

• 1 Craske J, Dilling N, Stern D. An outbreak of hepatitis associated with intravenous injection of Factor VIII concentrate. Lancet 1975; 2: 221-223
• 2 Fletcher ML, Trowell JM, Craske JM, Pavier K, Rizza CR. Non-A non-B hepatitis after transfusion of Factor VIII in infrequently treated patients. Brit Med J 1983; 287: 1754-1755
• 3 Kernoff PB, Lee CA, Karayannis P, Thomas HC. High risk of nonA-nonB hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effect of pooled human immunoglobulin. Brit J Haematol 1984; 58: 174-175
• 4 Hay CR, Preston FE, Triger DR, Underwood JC. Progressive liver disease in haemophilia: an understated problem?. Lancet 1985; 1: 1495-1498
• 5 Gabra GS, Crawford RJ, Mitchell R. Post-transfusion hepatitis. Brit Med J 1981; 283: 1-2
• 6 Norkrans G, Widel A, Teger-Nilsson AC, Kjellman H, Frosner S, Iwarson S. Acute hepatitis Non-A, Non-B following administration of Factor VIII concentrates. Vox Sang 1981; 41: 129-131
• 7 Barker LF, Butler R, Mannucci PM. et al What is the importance of the ‘Small Pool Concept’ in the preparation of Fraction I and Cryoprecipitates for the prevention of post-transfusion hepatitis?. Vox Sang 1980; 38: 106-119
• 8 Rouzioux C, Chamaret S, Montagner L, Carnelli V, Rolland G, Mannucci PM. Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate. Lancet 1985; 271-272
• 9 Felding P, Nilsson IM, Hansson BG, Biserfield G. Absence of antibodies to LAV/HTLV III in haemophiliacs treated with heat-treated Factor VIII concentrate of American origin. Lancet 1985; 2: 832-833
• 10 Petricciani JC, McDougal JS, Evatt BL. Case for concluding that heat-treated, licensed anti-haemophilic Factor is free from HTLV-III. Lancet 1985; 2: 890-891
• 11 Colombo M, Mannucci PM, Carnelli V, Savidge GF, Gazengel C, Schimpf K. Transmission of non-A, non-B hepatitis by heat-treated Factor VIII concentrate. Lancet 1985; 2: 1-4
• 12 Kernoff PB, Miller EJ, Savidge GF, Machin SJ, Dewar FE, Preston FE. Wet heating for safer Factor VIII concentrate?. Lancet 1985; 2: 721-722
• 13 Mannucci PM, Colombo M, Rodeghiero F. Non-A, non-B hepatitis after factor VIII concentrate treated by heating and chloroform. Lancet 1985; 2: 1013-1014
• 14 Rickard KA, Dority P, Batey RG, Johnson S, Campbell J, Hodgson J. Hepatitis and haemophilia therapy in Australia. Lancet 1982; 2: 146-148
• 15 Gabra GS, Crawford RJ, Mitchell R. Factor VIII cryoprecipitate and hepatitis risk. Lancet 1982; 2: 1220-1221
• 16 Stirling ML, Murray JA, McKay P, Black SH, Peutherer JF, Ludlam CA. Incidence of infection with hepatitis B virus in 56 patients with haemophilia A 1971-1979. J Clin Pathol 1983; 36: 577-580
• 17 Ludlam CA, Puetherer JF. Hepatitis B infection in haemophilia. Lancet 1982; 2: 776-777
• 18 Gomperts ED, Lazerson J, Berg D, Lockart D, Deavenport E. Hepatocellular enzyme patterns and hepatitis B exposure in multitransfused young and very young hemophilia patients. Am J Hematol 1981; 11: 55-59
• 19 Bird AG, Codd AA, Collins A. Hemophilia and AIDS. Lancet 1985; 1: 162-163
• 20 Mannucci PM. Hemophilia diagnosis and management: progress and problems. In: Recent Advances in Blood Coagulation Poller R. (ed.) Churchill Livingstone; Edinburgh: 1981
• 21 Colton T. Statistics in medicine. Little Brown & Co; Boston:
• 22 Breslow NE. Analysis of survival data under the proportional hazards model. Int Statist Rev 1975; 43: 45-49
• 23 Peto R, Pike MC, Armitage P. et al Design and analysis of randomized clinical trials requiring prolonged observations of each patient. II Analysis and examples. Brit J Cancer 1977; 35: 1-39
• 24 Bloom AL. Hemophilia and AIDS. Lancet 1985; 1: 336-337
• 25 Davis CE, Grizzle JE, Bryan JA. Estimation of the probability of post-transfusion hepatitis in hemophilia treatment. Biometrics 1973; 29: 386-392